Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.

doi:10.1016/S1470-2045(14)70212-8

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.

The Lancet. Oncology - 1 Jul 2014

Malka David, Cervera Pascale, Foulon Stéphanie, Trarbach Tanja, de la Fouchardière Christelle, Boucher Eveline, Fartoux Laetitia, Faivre Sandrine, Blanc Jean-Frédéric, Viret Frédéric, Assenat Eric, Seufferlein Thomas, Herrmann Thomas, Grenier Julien, Hammel Pascal, Dollinger Matthias, André Thierry, Hahn Philipp, Heinemann Volker, Rousseau Vanessa, Ducreux Michel, Pignon Jean-Pierre, Wendum Dominique, Rosmorduc Olivier, Greten Tim F

Abstract excerpt

BACKGROUND: Gemcitabine plus a platinum-based agent (eg, cisplatin or oxaliplatin) is the standard of care for advanced biliary cancers. We investigated the addition of cetuximab to chemotherapy in patients with advanced biliary cancers. METHODS: In this non-comparative, open-label, randomised phase 2 trial, we recruited patients with locally advanced (non-resectable) or metastatic cholangiocarcinoma, gallbladder...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aspartate Aminotransferases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bile Duct Neoplasms

Share to Bile Ducts, Intrahepatic

Share to Cholangiocarcinoma

Share to Gallbladder Neoplasms

Share to Gemcitabine

Share to Organoplatinum Compounds

Share to Oxaliplatin

Source

Open in PubMed Open full text

Identifiers

PMID: 24852116
DOI: 10.1016/S1470-2045(14)70212-8
PMCID: PMC6372099

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.PMID 24852116Read ↗

Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study.Semantic proximity Read ↗

PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study.Semantic proximity Read ↗

Randomized Phase II trial of combination chemotherapy with panitumumab or bevacizumab for patients with inoperable biliary tract cancer without KRAS exon 2 mutations.Semantic proximity Read ↗

Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study.Semantic proximity Read ↗

Phase II study of gemcitabine, oxaliplatin and capecitabine in patients with KRAS exon 2 mutated biliary tract cancers.Semantic proximity Read ↗

A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer.Semantic proximity Read ↗

Chemotherapy and targeted therapy for advanced biliary tract cancers：An umbrella reviewSemantic proximity Read ↗

Gemcitabine plus Oxaliplatin (GEMOX) combined with Atezolizumab and Bevacizumab for Advanced Biliary Tract Cancer: A Preliminary Observational StudySemantic proximity Read ↗

Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.Semantic proximity Read ↗

Systemic treatment of advanced or recurrent biliary tract cancer.Semantic proximity Read ↗

Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial.Semantic proximity Read ↗

Rational development of combination therapies for biliary tract cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.